BSE · 524202
Lactose (India) Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹118 Cr with net profit ₹5 Cr — a 4.38% net margin, versus 5.9% the period before.
Shareholding
As of 2026-06-30
- Promoter53.65%
- Public45.74%
- DII0.62%
16,554 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.8× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs · ranked #17 of 30 by market cap · medians across 25 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Divis Laboratories Ltd. | ₹2,06,402 Cr | 274.64 | 12.29 | 15.32% | 24.32% |
| Acutaas Chemicals Limited | ₹27,136 Cr | 206 | 16.41 | 21.54% | 26.6% |
| Neuland Laboratories Ltd. | ₹24,722 Cr | 116.25 | 13.26 | 19.42% | 17.99% |
| Jubilant Pharmova Ltd. | ₹15,559 Cr | 129.38 | 2.18 | 5.62% | 4.84% |
| Aarti Drugs Ltd. | ₹3,737 Cr | 67.68 | 2.41 | 12.58% | 7.6% |
| SMS Pharmaceuticals Ltd. | ₹3,706 Cr | 110.54 | 4.72 | 12.98% | 11.5% |
| Hikal Limited | ₹2,725 Cr | 188.86 | 2.28 | 3.03% | -2.88% |
| Beta Drugs Limited | ₹2,258 Cr | 249.4 | 9.23 | 16.95% | 10.78% |
| NGL Fine Chem Limited | ₹2,008 Cr | 148.87 | 6.1 | 14.62% | 9.59% |
| Fermenta Biotech Ltd. | ₹1,318 Cr | 67.23 | 3.16 | 17.67% | 13.66% |
| Lactose (India) Ltd.(this company) | ₹135 Cr | 22.2 | 2.08 | 9.36% | 3.72% |
AI analysis
AI-generated · google/gemini-2.5-flashLactose (India) Ltd. has a market capitalization of Rs 128 Cr. The company reported annual revenue of Rs 117.85 Cr in Mar 2025 and a net profit of Rs 5.16 Cr in the same period. Its book value per share is Rs 51.46, and it has an EPS of Rs 4.82.
Positives
- +Revenue grew significantly from Rs 35.28 Cr in Mar 2021 to Rs 117.85 Cr in Mar 2025.
- +The company's profit margin is high at 371.71%.
- +Net profit has shown recovery, moving from a loss of Rs 2.48 Cr in Mar 2021 to a profit of Rs 5.16 Cr in Mar 2025.
Negatives
- −A significant portion of promoter shares, 26.07%, are pledged as of Mar 2026.
- −The debt-to-equity ratio is 0.91, indicating reliance on debt financing.
- −EPS has fluctuated significantly, from -Rs 2.40 in Mar 2021 to Rs 5.39 in Mar 2024, and then Rs 4.10 in Mar 2025, suggesting inconsistent earnings.
- −Historical promoter shareholding data is not available from Mar 2016 to Dec 2018, preventing analysis of promoter holding trends.
Financial performance
The company's annual revenue increased from Rs 35.28 Cr in Mar 2021 to Rs 117.85 Cr in Mar 2025. Net profit also rose from a loss of Rs 2.48 Cr in Mar 2021 to a profit of Rs 5.16 Cr in Mar 2025. Quarterly revenue for Mar 2026 was Rs 45.77 Cr, with a net profit of Rs 1.88 Cr.
Profitability & returns
Lactose (India) Ltd. reported a return on equity (ROE) of 9.36% and a return on capital employed (ROCE) of 10.75%. The company's profit margin stood at 371.71%. Over the last five annual periods, EPS has fluctuated significantly, from -Rs 2.40 in Mar 2021 to Rs 5.39 in Mar 2024, before settling at Rs 4.10 in Mar 2025.
Balance sheet
The company maintains a debt-to-equity ratio of 0.91. The book value per share is Rs 51.46. Detailed quarterly balance sheet figures are not available in the provided data.
Ownership & pledges
As of Mar 2026, promoters held 53.6455% of the company's shares. Public shareholding was 45.7355%, and DIIs held 0.619%. A portion of promoter shares, specifically 26.07%, were pledged as of Mar 2026. This includes 220661 pledged shares by Atul Maheshwari and 1539910 by Sangita Maheshwari.
Regulatory & surveillance
No information regarding surveillance measures for Lactose (India) Ltd. was provided in the available data.
Data as of — price: 2026-07-29 · financials: Mar 25 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.